Attributes of children and adolescents with avoidant/restrictive food intake disorder. by Keery, Helene et al.
UCSF
UC San Francisco Previously Published Works
Title
Attributes of children and adolescents with avoidant/restrictive food intake disorder
Permalink
https://escholarship.org/uc/item/6rh0z569
Journal
Journal of Eating Disorders, 7(1)
Authors
Keery, Helene
LeMay-Russell, Sarah
Barnes, Timothy L
et al.
Publication Date
2019-12-01
DOI
10.1186/s40337-019-0261-3
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
RESEARCH ARTICLE Open Access
Attributes of children and adolescents with
avoidant/restrictive food intake disorder
Helene Keery1, Sarah LeMay-Russell1, Timothy L. Barnes1,2, Sarah Eckhardt1, Carol B. Peterson3,4, Julie Lesser1,
Sasha Gorrell5 and Daniel Le Grange5,6*
Abstract
Background: Avoidant/Restrictive Food Intake Disorder (ARFID) is a comparatively new DSM-5 diagnosis. In an
effort to better understand this heterogeneous patient group, this study aimed to describe the physical and
psychological attributes of children and adolescents with ARFID, and to compare them to patients with full-
threshold or atypical anorexia nervosa (AN).
Methods: Children and adolescents aged 7-to-19 years (N = 193) were examined upon presenting at a pediatric
eating disorder center between July 2015 and December 2017. Data included diagnosis assessed via the semi-
structured Eating Disorder Examination interview along with measures of anthropometrics, depression, anxiety, self-
esteem, perfectionism and clinical impairment.
Results: Compared to AN and atypical AN (n = 87), patients with ARFID (n = 106) were significantly younger (12.4
vs. 15.1 years, p < .0001), male (41% vs. 15%, p < .0002), and were more likely to be diagnosed with at least one co-
morbid DSM-5 diagnosis (75% vs. 61%, p = .04). Patients with ARFID were less likely to be bradycardic (4.7% vs.
24.1%, p < .0001), amenorrheic (11.1 and 34.7%, p = .001), admitted to the hospital (14.2% vs. 27.6%, p = .02), and
have a diagnosis of depression (18.9% vs. 48.3%, p < .0001). Patients with ARFID were significantly less likely to
experience acute weight loss vs. chronic weight loss as compared with those with AN or atypical AN (p = .0001). On
self-report measures, patients with ARFID reported significantly fewer symptoms of depression, anxiety,
perfectionism, clinical impairment, concerns about weight and shape, and higher self-esteem than patients with AN
or atypical AN (all ps < .0001). No differences were observed by race, anxiety disorder, orthostatic instability, suicidal
ideation, and history of eating disorder treatment.
Conclusions: Study results highlight the clinical significance of ARFID as a distinct DSM-5 diagnosis and the
physical and psychological differences between ARFID and AN/atypical AN. The novel finding that ARFID patients
are more likely than those diagnosed with AN to experience chronic, rather than acute, weight loss suggests
important related treatment considerations.
Keywords: Avoidant/restrictive food intake disorder, Anorexia nervosa, Atypical anorexia nervosa, Pediatric eating
disorder
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Plain English summary
This study describes physical and psychological attri-
butes of children and adolescents with DSM-5 Avoi-
dant/Restrictive Food Intake Disorder (ARFID) and
compares them to patients with full-threshold or atypical
anorexia nervosa (AN). Estimates of the percentage of
patients with ARFID range from 5 to 41%. Comparisons
to patients with AN have yielded inconsistent findings,
but generally indicate that patients with ARFID are more
likely to be younger, male, and have longer duration of
illness. This is the largest study (n = 106) describing pa-
tients diagnosed with ARFID using formal DSM-5 cri-
teria. By comparing patients with ARFID to those with
AN/atypical AN, this study supports the separation of
the diagnosis from other eating and feeding disorders.
Findings also underscore the critical necessity of better
understanding this unique patient population, which will
ultimately improve early detection, and treatment
efforts.
Introduction
Avoidant/Restrictive Food Intake Disorder (ARFID) is a
comparatively new eating disorder diagnosis in the Diag-
nostic and Statistical Manual of Mental Disorder, Fifth
Edition (DSM-5) [1]. Historically, while patients with
Food Avoidance Emotional Disorders were distinguish-
able from patients with anorexia nervosa (AN) thirty
years ago [2], still relatively little is known about this
heterogeneous group of patients and the extent to which
ARFID may be similar or different from other types of
restricting eating disorders [3]. ARFID was included in
the DSM-5 to better capture the range of developmental
feeding and eating problems as well as to more accur-
ately diagnose patients who previously were diagnosed
with an Eating Disorder Not Otherwise Specified or
Feeding Disorder of Infancy or Early Childhood in earl-
ier versions of the DSM [4, 5]. While patients with
ARFID often present as underweight due to either long-
term malnutrition or restriction of intake that causes a
significant amount of weight loss, they do not experience
the body image disturbance that is characteristic of pa-
tients with AN or atypical AN. Accumulating clinical
data also suggest that ARFID may have distinct “sub-
types.” However, these subtypes have not been formal-
ized, and different studies have proposed varying
categorizations, including selective eating, generalized
anxiety, medical, food allergies, Autism Spectrum/Devel-
opmental Disorder, and food avoidant emotional dis-
order [1, 6–8], and more recently, the three categories of
limited intake, limited variety, and aversive [9].
Recent research has provided information about the
prevalence of ARFID as well as how children and adoles-
cents with this diagnosis are similar to or different from
those with AN. One study estimated the prevalence of
ARFID in school children aged 8–13 years at 3.2% [10].
In outpatient adolescent medicine eating disorder clinics,
estimates of patients diagnosed with ARFID range from
5 to 41% [3, 11–13]. Another study found that the
prevalence of ARFID was 39% in an adolescent eating
disorder day treatment program [14], and even higher
(43%) in a sample of patients aged 6–12 years presenting
with significant weight loss to an eating disorder clinic
[15]. Comparisons to patients with AN generally indicate
that ARFID patients are more likely to be younger, male,
and have a longer duration of illness [3, 13, 15]. ARFID
patients also have been found to be equally or more
likely to have an anxiety disorder diagnosis and less
likely to have a diagnosis of depression than those with
AN [3, 14]. Finally, patients who fit criteria for ARFID
tend to be underweight, although not to the same degree
as patients with AN [3, 11, 14, 15].
Most of the previous studies comparing ARFID and
AN/atypical AN have been retrospective chart reviews
and used the proposed DSM-5 criteria for ARFID [3,
11–14]. A retrospective chart review published in 2018
used the formal DSM-5 criteria to identify 31 patients
(8.4%) with an ARFID diagnosis but did not compare
these patients with another group (i.e., AN) [16]. A re-
cent overview of patients with ARFID in tertiary care
was restricted by the younger age of its sample (i.e.,
under age 13) [17]. A description of patient characteris-
tics based prospectively on the current criteria is war-
ranted as this diagnosis gains more attention. Efforts to
enhance our understanding of a still largely unknown
diagnostic syndrome are of critical importance in im-
proving early detection of ARFID, as well as in inform-
ing the development of tailored treatment interventions
for this unique disorder. The aim of the present study
was to compare ARFID with other restrictive eating dis-
orders (AN and atypical AN) among patients presenting
at a specialist community-based eating disorder service.
This objective placed ARFID in context with broader
eating disorder diagnoses, used both physical and psy-
chological measures, and assessed patients at the time of
presentation using DSM-5 criteria.
Methods
This study examines baseline data from a longitudinal
study designed to evaluate the effectiveness of evidence-
based outpatient treatments for eating disorders. This
study was approved by the Children’s Minnesota Institu-
tional Review Board.
Setting and participants
The Center for the Treatment of Eating Disorders
(CTED) is a service within Children’s Minnesota that of-
fers a multi-disciplinary approach to provide specialized
care for eating disorders. The outpatient clinic treats
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patients aged 7 years and older, while the inpatient ser-
vice treats those aged 7–21 years. Over 250 patients
present for evaluation at CTED annually. Owing to a
known special interest in treating ARFID, CTED receives
increased referrals for this specific patient population
from local medical providers (e.g., gastrointestinal
specialists).
To be eligible for participation in the study, a patient
had to: 1) be 7–19 years old; 2) present for an intake
evaluation of eating disorder symptoms; 3) be diagnosed
with a DSM-5 feeding or eating disorder; and 4) agree to
participate in outpatient treatment. Study data were col-
lected between July 2015 and December 2017. All eli-
gible patients presenting for treatment were approached
for participation in the study, and after obtaining in-
formed consent (assent for patients < 18 years), research
staff collected data from patients via interviews, pen-
and-paper assessments, and electronic health records.
Assessment and measures
Enrolled patients were evaluated by a psychiatrist, psycholo-
gist or clinical social worker, and trained assessors who ad-
ministered measures at the time of the family’s first
encounter with our service (inpatient or outpatient). Pa-
tients were admitted to the inpatient unit if they were de-
termined to be medically unstable by the attending
psychiatrist according to recommended guidelines of the
American Academy of Pediatrics and the Society of Adoles-
cent Medicine [18].
Patients completed age-appropriate self-report mea-
sures, and parents were given standardized assessments to
complete about their child. The intake questionnaire in-
cluded questions about eating disorder treatment history,
current psychotropic medications, and medical history to-
gether with other medical conditions, including gastro-
intestinal and endocrine disorders. To determine eating
disorder diagnosis, patients ages 12 years and older com-
pleted the EDE [19], which was also used to assess eating
disorder symptom frequency severity as well as concerns
about eating, weight, and shape. Patients younger than 12
years old were given a diagnosis agreed upon by the clini-
cians involved in the assessment after their diagnostic
evaluations. Psychiatric assessment included MINI-Kid
[20] to evaluate self-harm and suicidal ideation, the Child
Depression Inventory 2nd Edition (CDI-2 [21]) to assess
depressive symptoms, and the Rosenberg Self-Esteem Scale
(RSE [22]) to assess self-esteem. The Beck Anxiety Inven-
tory (BAI) [23] was used to assess anxiety, the Clinical Im-
pairment Assessment [24] (CIA) to assess the psychosocial
impact of the eating disorder, and the Clinical Perfection-
ism Questionnaire (CPQ [25]) to assess perfectionism out-
side of eating, weight or appearance. Parent reports of
their child’s anxiety and depression were assessed using
the internalizing scale of the Child Behavior Check List
(CBCL) [26].
DSM-5 eating disorder and comorbid diagnoses were
agreed upon by providers based on results from the
EDE, semi-structured diagnostic assessment, MINI-Kid,
and patient/parent report of symptoms. When patient
and parent report differed, objective medical data re-
garding growth, weight loss, and medical stability were
used to inform the diagnostic decision.
Medical assessment, including orthostatic vitals (su-
pine and standing pulse rate and blood pressure), and
weight were measured by a medical assistant or nurse.
Bradycardia was defined as supine pulse rate of < 50
beats per minute, hypotension as < 90 mmHG, and
orthostatic instability as difference in supine and stand-
ing heart rate of > 20 beats per minute or difference of
> 10mm HG in supine and standing blood pressure [17].
Amenorrhea was defined as the absence of menarche in
girls age 15 years or older (primary) or the lack of men-
ses for the past 3 months (secondary) [27].
AN cases were identified using a weight threshold of
< 89% of expected body weight (%mBMI = BMI/50th
percentile BMI for age and gender × 100) [28]. Patients
who met all DSM-5 diagnostic criteria for AN and had a
weight of > 90%mBMI were identified as atypical AN
[29]. There was no upper level cut-off in BMI for an
atypical AN diagnosis.
Statistical analyses
All demographic, medical, and psychological measures
were calculated as means and standard deviations for
continuous variables and proportions for categorical var-
iables. Initial analyses for demographic and weight pres-
entation consisted of comparing measures across all
three diagnoses. Analysis of variance (ANOVA) was ap-
plied for continuous variables (e.g., age, weight, and
BMI) and χ2 or Fisher’s exact test was used, when ap-
propriate, for categorical variables. Post hoc pairwise
comparisons between individual eating disorder groups
were also utilized to denote significance. As demon-
strated by previous analyses by Sawyer and colleagues
[30], data suggested that patients with AN and atypical
AN differ by weight at presentation but do not differ sig-
nificantly on other variables of interest. Further, al-
though patients with AN and atypical AN differed
significantly on weight presentation in our cohort, their
scores on other medical and psychological measures did
not differ significantly. As a result, and due to concerns
about small sample sizes in stratified analyses, all further
analyses compared the ARFID group to the AN and
atypical AN patients combined (AN/atypical AN group;
n = 87). Patients with ARFID were compared with those
with AN and atypical AN by using independent t-tests
for continuous variables (mean difference) and χ2 or
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Fisher’s exact tests for categorical variables (odds ratios).
Between-group differences were assessed with a signifi-
cance threshold of p < .05. All statistical analyses were
performed in SAS 9.4 (Cary, NC).
Results
Of the 404 patients who presented for evaluation at
CTED during the study period, 338 (84%) met initial eli-
gibility. After evaluation, 266 (66%) were verified as eli-
gible, of which 243 patients were diagnosed with a
DSM-5 eating disorder and enrolled in the present
study. Of the 243 enrolled patients, 54 patients were di-
agnosed with AN, 36 with atypical AN, and 111 patients
with ARFID (Table 1). Of those enrolled, certain exclu-
sion criteria precluded their inclusion in analyses. Specif-
ically, after accounting for individuals with binge/purge
eating disorders who were not underweight (n = 17), in-
dividuals diagnosed with unspecified feeding and eating
disorders (n = 24), and patients with missing data (n =
8), the final data set for analyses consisted of 193 pa-
tients. Within the 193 cases included in analyses, 52
(26.9%) met criteria for AN, 35 (18.1%) met criteria for
atypical AN, and 106 (54.9%) met criteria for ARFID.
Demographic characteristics are presented in Table 2.
The mean age for patients with ARFID was 12.4 years
compared to 15.1 years for AN and 15.2 years for atyp-
ical AN groups, respectively (p < .0001). Over 40% of pa-
tients with ARFID were male, compared to 15 and 11%
of patients with AN/atypical AN (p = .0002). Most pa-
tients (≥ 80%) were White/Caucasian, with no significant
differences across racial groups except for Hispanic eth-
nicity. When examining weight, patients with ARFID
presented with a lower weight (37.6 kg, SD = 12.0 kg) on
average compared to the AN/atypical AN group (44.4
kg, SD = 8.5 kg, and 56.7 kg, SD = 7.5 kg, respectively). In
addition, the ARFID group presented with a significantly
lower BMI, BMI z-score, and %mBMI compared to the
AN/atypical AN group. While lower weight might be ex-
pected given the lower average age of those diagnosed
with ARFID, these patients were the least likely to ex-
perience acute weight loss (vs. chronic weight loss)
(14.9%), as compared with AN (40.0%) and atypical AN
(50.0%) (p = .0001).
When comparing patients with ARFID to the AN/
atypical AN group, significant differences between vital
signs and medical instability were observed (Table 3).
Pulse rate (78.8 vs. 63.4, p < .0001) and systolic blood
pressure (113.1 vs. 109.7, p = .02) were all significantly
higher for the ARFID than for the AN/atypical AN
group. The ARFID group was significantly less likely to
be bradycardic (OR = 0.16, p < .0001), amenorrheic
(OR = 0.24, p = .001), and admitted to the hospital (OR =
0.43, p < .02) compared to the AN/atypical AN group.
ARFID and AN/atypical AN groups did not differ on
measures of hypotension, orthostatic instability, or his-
tory of prior eating disorder treatment (all ps > .05).
Using χ2 analyses, patients with ARFID were less likely
than the AN/atypical AN group to be diagnosed with
depression (OR = 0.25, p < .0001), but more likely to have
an existing psychiatric comorbidity (OR = 1.88, p = .04)
(Table 4). Furthermore, nearly 24% of patients with
ARFID had a diagnosis of attention-deficit/hyperactivity
disorder (ADHD) compared to only 1.15% in the AN/
atypical AN group (p < .0001). Compared to the AN/
atypical AN group, patients with ARFID scored signifi-
cantly lower on the Global EDE (0.34 vs. 2.56, p < .0001)
and corresponding subscales. In addition, patients with
ARFID scored significantly lower on the self -report
CDI-2 (53.2 vs. 62.0, p < .0001), the CPQ (19.4 vs. 25.8,
p < .0001), the CIA (10.2 vs. 22.4, p < .0001), and BAI
Total Score (10.2 vs. 16.1, p = .002). Patients with ARFID
also scored significantly higher on the Rosenberg Self-
Esteem (21.9 vs. 15.2, p < .0001) compared to the AN/
atypical AN group. There were no statistical significant
differences on the parental report of CBCL Internalizing
T-Score (61.8 vs. 63.6, p = .34) or self-report on self-
harm/suicidal ideation (9.4 vs. 13.6, p = .47).
Discussion
The aim of this study was to provide a comprehensive
comparison of the unique physical and psychological
presentation of patients diagnosed with ARFID accord-
ing to DSM-5 guidelines when compared to patients
with AN and atypical AN. First, this study found that
while smaller stature may be expected given the younger
age of this subgroup, ARFID patients were significantly
lower in weight than both AN/atypical AN patients.
Additionally, patients with ARFID were equally ortho-
static as the AN/atypical AN group, but were less likely
to be amenorrheic, admitted to the hospital, or on psy-
chiatric medication. While patients with AN were more
Table 1 Distribution of total eating disorder diagnoses at CTED,
July 2015 – December 2017 (n = 243)
Diagnosis n %
Anorexia Nervosa (AN) 54 22.2
Bulimia Nervosa (BN) 9 3.7
Binge Eating Disorder (BED) 2 0.8
Avoidant/Restrictive Food Intake (ARFID) 111 45.7
Other specified feeding or eating disorder
Atypical AN 36 14.8
AN: limited body image/ behaviors – –
BN: low frequency duration 1 0.4
BED: low frequency duration 1 0.4
Purging Disorder 4 1.6
Unspecified Feeding or Eating Disorder 24 9.9
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likely to be older and female, which likely affected com-
parative rates of amenorrhea among those with ARFID,
overall, the physical differences identified in the current
study highlight the importance of thorough medical as-
sessments to determine the impact of low presenting
weight. In one recent study, latent class analysis was
used to silo eating disorder symptoms into groups that
reflected the DSM-5 diagnostic categories of AN and
ARFID [31]. For the most part, the findings of Pinhas
and colleagues [31] align with our results, regarding be-
tween-group differences in age, prior hospitalization,
eating disorder symptomology, and rates of psychiatric
comorbidity. However, in Pinhas et al. [31], AN patients
were more likely to have unstable vital signs whereas in
Table 2 Demographic and weight presentation of study participants with AN, Atypical AN, and ARFID (n = 193)
AN n = 52 Atypical AN n = 35 ARFID n = 106 p a
M (SD) or n (%) M (SD) or n (%) M (SD) or n (%)
Age 15.06 (1.96)* 15.23 (1.88)* 12.39 (2.65)** <.0001
Gender
Male 8 (15.38)* 4 (11.43)* 43 (40.57)** .0002
Female 44 (84.62) 31 (88.57) 63 (59.43)
Race/Ethnicity
White/Caucasian 45 (86.54) 28 (80.00) 87 (82.08) .69
Black/African-American 0 (0) 1 (2.86) 2 (1.89) .75b
Hispanic/Latino 0 (0)** 6 (17.14)* 9 (8.49)* .005b
Asian 4 (7.69) 0 (0) 4 (3.77) .25b
Weight Presentation
Kilograms 44.41 (8.50)* 56.67 (7.50)** 37.61 (11.97)*** <.0001
BMI 16.63 (1.74) * 20.66 (2.11)** 16.09 (2.67)*** <.0001
BMI z-score −1.59 (1.00)* 0.21 (0.62)** −1.49 (1.45)* <.0001
%mBMI 83.11 (7.75)* 103.33 (11.54)** 86.40 (14.87)* <.0001
Acute Weight Loss (vs. Chronic)c 16 (40.0%)* 12 (50.0%)* 15 (14.9%)** .0001
aAnalyzed using Pearson’s Chi-square test for categorical variables or ANOVA for continuous variables, unless noted differently. b Due to small cell count, analyzed
using Fischer’s Exact test. c Data missing for 28 patients (for AN: n = 12, for Atypical AN: n = 11, and for ARFID: n = 5). Race/Ethnicity excludes patients who
declined to respond or selected “other” (n = 7). */**/*** Denotes significance between eating disorder groups using pairwise comparisons (p < .05)
Table 3 Medical presentation of study participants with AN/Atypical AN, and ARFID (n = 193)
AN or Atypical AN (n = 87) ARFID (n = 106) OR or
Mean
Difference
P a
M (SD) or n (%) M (SD) or n (%)
Vital Signs
Pulse rate 63.44 (16.62) 78.80 (15.91) −15.35 < .0001
Systolic blood pressure 109.7 (12.09) 113.1 (9.42) −3.35 .04
Diastolic blood pressure 61.57 (6.71) 63.43 (7.70) −1.86 .07
Medical Instability
Bradycardia, < 50 beats per minute 21 (24.14) 5 (4.72) 0.16 < .0001b
Hypotension, systolic pressure < 90 mmHg 4 (4.60) 2 (1.89) 0.40 .41b
Orthostatic Instability, > 20 beats per minute, > 10 mmHg 48 (55.17) 57 (53.77) 0.95 .85
Admitted/In hospital at presentation 24 (27.59) 15 (14.15) 0.43 .02
Amenorrheac 26 (34.67) 7 (11.11) 0.24 .001
Prior Eating Disorder Treatment 33 (37.93) 40 (37.74) 0.99 .98
Psychotropic medication 34 (39.08) 38 (35.85) 0.87 .64
Other medical condition present potentially impacting weightd 7 (8.05) 13 (12.26) 1.60 .34
aAnalyzed using Pearson’s Chi-square test for categorical variables or independent t-tests for continuous variables, unless noted differently. b Due to small cell
count, analyzed using Fischer’s Exact test. c Excludes males (for AN/atypical AN, 12 excluded; for ARFID, 43 excluded). d Conditions considered included
gastrointestinal or endocrine disorders including, but not limited to delayed gastric emptying, gastritis, esophagitis, GERD, Grave’s disease, Type 1 Diabetes,
chronic constipation, food allergies, acid reflux, celiac disease, irritable bowel syndrome, hypothyroidism, Hashimoto’s disease, and gastroparesis
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our sample, vital signs were comparable with the excep-
tion of bradycardia. Patients with ARFID in the current
sample were also less likely to experience acute weight
loss, suggesting that future study may benefit from
examining rates of weight loss and related consequences
for vital sign stability among children and adolescents
with ARFID.
Given that the ARFID classification was more recently
established in the DSM-5 [1], relatively little research
has been published on this population to date. Previous
studies describing this population have used retrospect-
ive chart reviews and/or assigned patients an ARFID
diagnosis based on the proposed DSM-5 criteria [3, 11–
15], while our data was prospectively collected and was
based on a DSM-5 ARFID diagnosis via a clinician inter-
action with each patient. Other recent study using the
latest diagnostic criteria has been limited by either a re-
stricted age range (i.e., only those aged 13 and younger)
[17] or had a substantially smaller sample (n = 31) and
did not include a comparison group [16]. With an
adequately powered sample across a broad age range
(i.e., 7–19), our study shows consistency in weight status
with previous literature that has characterized patients
diagnosed either retrospectively or prospectively with
ARFID. Of note, in the current study, patients with
ARFID had a lower %mBMI than those diagnosed with
AN, which lies in contrast to evidence from prior work
indicating patients who fit criteria for ARFID tend to be
less underweight than patients with AN [3, 11, 14, 15].
Our findings may be partially explained by the fact that
those diagnosed with ARFID in the current sample were
also on average, younger in age, and therefore expected
to present smaller in stature. However, %mBMI is calcu-
lated based upon metrics correspondent to age and
height, suggesting that our findings would benefit from
replication in future investigation. Patients with ARFID
in our sample were also more likely than the AN/atyp-
ical AN group to be younger and male [3, 12]. Diagnosis
with a comorbid DSM-5 disorder was a common feature
between our findings and those of other studies as well
Table 4 Psychiatric measures of participants with AN/Atypical AN, and ARFID (n = 193)
AN or Atypical AN (n = 87) ARFID (n = 106) OR or
Mean
Difference
p a
M (SD) or n (%) M (SD) or n (%)
Diagnoses
Psychiatric comorbidity (any DSM-V diagnosis) 53 (60.92) 79 (74.53) 1.88 .04
ADHD 1 (1.15) 25 (23.58) 26.54 < .0001b
Autism 1 (1.15) 6 (5.66) 5.16 .13b
Depressive Disorderc 42 (48.28) 20 (18.87) 0.25 < .0001
Anxiety Disorderd 41 (47.13) 61 (57.55) 1.52 .15
Eating Disorder Examinatione
Global score 2.56 (1.58) 0.30 (0.34) 2.25 < .0001
Restraint 2.83 (1.77) 0.29 (0.59) 2.55 < .0001
Eating concerns 1.66 (1.52) 0.32 (0.55) 1.33 < .0001
Shape concerns 2.61 (1.83) 0.33 (0.53) 2.28 < .0001
Weight concerns 3.11 (1.95) 0.27 (0.43) 2.85 < .0001
Parent Report
CBCL Internalizing T-Scoref 63.56 (10.22) 61.84 (11.53) 1.73 .34
Self-Report Measures
vSelf-harm/ Suicidal ideation (MiniKid)f 10 (15.63) 8 (10.00) 0.60 .31
Children’s Depression Inventory (Total T Score)f 61.97 (14.59) 53.18 (10.56) 7.87 < .0001
Rosenberg Self-Esteemf 15.19 (7.85) 21.85 (6.06) −6.66 < .0001
Beck Anxiety Inventory Total Scoree 16.07 (11.50) 10.17 (9.24) 5.90 .001
Clinical Impairment Assessmente 22.39 (13.03) 10.15 (8.98) 11.24 < .0001
Clinical Perfectionism Questionnairee 25.75 (6.85) 19.38 (4.84) 6.37 < .0001
aAnalyzed using Pearson’s Chi-square test or for categorical variables or independent t-tests for continuous variables. b Due to small cell count, analyzed using
Fischer’s Exact test. c Patient is considered to have diagnosis of depression if they were diagnosed with Dysthymia, Major Depressive Disorder, Other Specified
Depressive Disorder, and/or Unspecified Depression. d Patient is considered to have an anxiety diagnosis consists if they were diagnosed with OCD, PTSD, Social
Anxiety Disorder, Agoraphobia, Generalized Anxiety Disorder, Panic Disorder, Separation Anxiety Disorder, Specific Phobia, Other Specified Anxiety Disorder, and/
or Unspecified Anxiety. e Restricted to patients age ≥ 12 (for AN: n = 81, for ARFID: n = 63) and existing values for EDE subscales, BAI, CIA, and BAI (for AN: n = 75,
for ARFID: n = 53). f Removed missing values for internalizing t-score, self-harm, total t-score, and RSE (for AN: 23 excluded, for ARFID: 26 excluded)
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[3, 16]. With regard to our inclusion of atypical AN, we
saw similarity to a previous study; patients in our study
with AN and atypical AN were observed to have similar
levels of psychopathology despite the significant differ-
ences in their %mBMI [30]. Notably, those with ARFID
were significantly more likely to be diagnosed with
ADHD than either AN or atypical AN. While this differ-
ence is perhaps reflective of elevated population rates of
ADHD among males, future research might investigate
this specific comorbidty as a clinical feature of ARFID,
with particular attention paid to the impact of stimulant
medication use on appetite and clinical presentation.
Further, given the significantly higher rates of ADHD ev-
idenced among those diagnosed with ARFID in the
current study, and the known comorbidity between
ADHD and Autism Spectrum/Developmental Disorder,
future work should more specifically investigate this po-
tential shared diagnostic risk.
There are several limitations to this study. First, the
sample is primarily white, which limits generalizability.
Also, we combined AN and atypical AN because of
power concerns; however, as demonstrated by Sawyer et
al. [30] and our own analyses, no significant group dif-
ferences were observed on medical and psychological
variables. Further, due to the small sample size of chil-
dren 12 and younger, we were not able to compare the
children aged 12 and under on a measure of anxiety. Fi-
nally, lack of information on duration of illness did not
allow for between-group comparisons. While the current
study indicates that those with ARIFD were more likely
to experience chronic vs. acute weight loss, it is note-
worthy that assessment of duration of illness in ARFID
patients can be difficult given that on average, patients
meeting criteria for this disorder have extended duration
of illness compared to patients diagnosed with AN, atyp-
ical AN and bulimia nervosa [3, 13, 15]. Further, assess-
ment measures specifc to ARFID have been slow to
emerge; while this study used a rigorous method with
which to determine ARFID diagnosis, future study
should rely upon empirically validated measures, specif-
ically oriented toward a determination of this diagnosis.
The current study uniquely identified differences across
disorders in acute vs. chronic weight loss. Specifically, those
with ARFID were less likely to experience acute vs. chronic
weight loss as compared with AN and atypical AN counter-
parts. Restrictive eating disorders and weight loss have a sig-
nificant negative impact on both the physical and
psychological functioning of children and adolescents [27].
Research suggests that in patients with AN, weight loss and
malnutrition are associated with a number of significant life-
threatening medical complications including hypotension,
bradycardia, and hypothermia [32]. Weight loss in patients
with AN has also been associated with atrophy of the brain
and decreased cognitive functioning [32]. Similarly, Sawyer
et al. demonstrated that adolescents diagnosed with atypical
AN have similar medical and psychological impairments as
patients with full-threshold AN [30]. However, there are not
yet any published studies investigating the physical and psy-
chological effects of weight loss and malnutrition in patients
with ARFID; this would be an important area for future
study following the descriptive work in the evidence base to
date. Learning that patients with ARFID were significantly
less likely to experience acute weight loss vs. chronic weight
loss as compared with those with AN or atypical AN, may
be critical in informing future screening efforts. For example,
it is possible that a sizeable portion of ARFID patients might
be missed if we focus only on those who present at low
weight, or those who appear to have lost weight precipi-
tously. Evidence that patients who meet criteria for ARFID
are significantly younger than youth with AN and atypical
AN, along with potential health consequences associated
with sustained low weight, underscores a critical line of fu-
ture inquiry in this unique patient population.
This study provides additional data to support the valid-
ity of separating ARFID from other eating and feeding dis-
orders including AN and atypical AN. Given the relative
newness of the diagnosis, ARFID patients may not be de-
tected as early or often as those with more traditionally
described AN/atypical AN, leading to reduced access to
care. Early detection of ARFID may lead to faster
mobilization of treatment efforts and potentially better ill-
ness prognoses. As such, our findings based on formal
DSM-5 criteria in a sizable sample of individuals with
ARFID provide an important foundation for future efforts
to better define this clinical syndrome and to ultimately
tailor precision interventions for this population.
Conclusions
The current study was uniquely able to examine clinical
features of a large treatment-seeking sample of children
and adolescents diagnosed with ARFID. Findings from
this study highlight the clinical significance of ARFID as
a distinct DSM-5 diagnosis and describe the physio-
logical and psychological presentation of this disorder.
The novel finding that ARFID patients are more likely
than those diagnosed with AN to experience chronic, ra-
ther than acute, weight loss should be further investi-
gated, along with associated health consequences. Given
the medical and psychiatric heterogeneity of this popula-
tion, further research is also needed to examine potential
differences between ARFID subgroups, as well as to de-
velopment reliable and valid assessment measures for
ARFID that can further improve understanding of this
clinical syndrome. The current study provides an im-
portant foundation in understanding medical and psy-
chological features of children and adolescents
presenting for treatment with ARFID.
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